FDA Authorizes First mRNA Flu Vaccine for Older Adults

The U.S. FDA has approved mFLUSIVA, Moderna's first mRNA-based seasonal influenza vaccine, for individuals aged 50 and above. Expected for the 2026-2027 flu season, this vaccine showed safety and potential for enhanced protection in trials with approximately 40,000 participants. This marks a significant advancement in influenza prevention technology.